These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 11269899

  • 1. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics.
    Karakaya G, Kalyoncu AF.
    Allergol Immunopathol (Madr); 2000; 28(6):319-21. PubMed ID: 11269899
    [Abstract] [Full Text] [Related]

  • 2. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
    Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z.
    J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
    [Abstract] [Full Text] [Related]

  • 3. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, Dama AR.
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D, Heeley E, Hughes K, Shakir SA.
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [Abstract] [Full Text] [Related]

  • 5. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs.
    Senna GE, Passalacqua G, Dama A, Crivellaro M, Schiappoli M, Bonadonna P, Canonica GW.
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):393-6. PubMed ID: 14768525
    [Abstract] [Full Text] [Related]

  • 6. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Swaak AJ, Theunissen DJ.
    Ned Tijdschr Geneeskd; 2001 Jul 28; 145(30):1476-7; author reply 1477-8. PubMed ID: 11503322
    [No Abstract] [Full Text] [Related]

  • 7. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Houben JJ, Liem B.
    Ned Tijdschr Geneeskd; 1999 Nov 13; 143(46):2338. PubMed ID: 10589225
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D, Heeley E, Hughes K, Shakir SA.
    Rheumatology (Oxford); 2003 Nov 13; 42(11):1342-53. PubMed ID: 12832706
    [Abstract] [Full Text] [Related]

  • 9. Relative safety of meloxicam in NSAID-intolerant patients.
    Kosnik M, Music E, Matjaz F, Suskovic S.
    Allergy; 1998 Dec 13; 53(12):1231-3. PubMed ID: 9930610
    [No Abstract] [Full Text] [Related]

  • 10. Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
    Çelik GE, Erkekol FÖ, Aydın Ö, Demirel YS, Mısırlıgil Z.
    Allergol Immunopathol (Madr); 2013 Dec 13; 41(3):181-8. PubMed ID: 23031659
    [Abstract] [Full Text] [Related]

  • 11. Re: Layton et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Degner F, Lesaffre E, Zeidler H.
    Rheumatology (Oxford); 2004 May 13; 43(5):680-1; author reply 681-2. PubMed ID: 15103042
    [No Abstract] [Full Text] [Related]

  • 12. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
    MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D.
    Gut; 2003 Sep 13; 52(9):1265-70. PubMed ID: 12912856
    [Abstract] [Full Text] [Related]

  • 13. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A.
    Ann Allergy Asthma Immunol; 2005 Jan 13; 94(1):34-8. PubMed ID: 15702813
    [Abstract] [Full Text] [Related]

  • 14. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
    Kruse R, Ruzicka T, Grewe M.
    Acta Derm Venereol; 2003 Jan 13; 83(3):183-5. PubMed ID: 12816152
    [Abstract] [Full Text] [Related]

  • 15. Celecoxib- and rofecoxib-induced delirium.
    Macknight C, Rojas-Fernandez CH.
    J Neuropsychiatry Clin Neurosci; 2001 Jan 13; 13(2):305-6. PubMed ID: 11449042
    [No Abstract] [Full Text] [Related]

  • 16. Meloxicam-induced erythema multiforme.
    Nikas SN, Kittas G, Karamaounas N, Drosos AA.
    Am J Med; 1999 Nov 13; 107(5):532-4. PubMed ID: 10569318
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.
    Quiralte J, Sáenz de San Pedro B, Florido JJ.
    Ann Allergy Asthma Immunol; 2002 Jul 13; 89(1):63-6. PubMed ID: 12141722
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.